Unicycive Therapeutics, Inc. (UNCY) stock intrinsic value fair value estimate & owner earnings analysis

Unicycive Therapeutics is a clinical-stage drug developer with no product on the market. Its lead candidate is oxylanthanum carbonate (OLC), a phosphate binder for patients with chronic kidney disease on dialysis. It has no product revenue. Its only reported revenues were $951 thousand in 2022 and $675 thousand in 2023. Operating cash outflow has grown from $5.8 million in 2021 to $31.3 million in 2025. Where it stands. The FDA accepted the new drug application for OLC in November 2024 with a decision date of June 28, 2025. In June 2025 the FDA issued a complete response letter because a third-party manufacturing vendor was cited for deficiencies after a cGMP inspection. The company resubmitted in December 2025, and the FDA set a new decision date of June 29, 2026. The company warned that if the vendor fails inspection again or the application is rejected again, it must resubmit and the timeline extends by another 6 to 12 months. The filings available to us do not include the outcome of that decision. How we value it. We measure what the business earns for its shareholders after operating cash flow, working capital swings, stock compensation and the capital spending needed to stay in business. On that basis the company lost about $1.76 per share in 2025, and it has lost money on this basis in every year we could measure (2021 through 2025). Stock compensation, which is a real cost, was $2.6 million in 2025 and is deducted. Nothing in the business today produces positive earnings: there is no approved product for sale. A pending FDA decision is a hoped-for event, not something the company has already achieved, so it is not credited to any case. The three cases. Bear, base and bull are each worth $0 per share, because in each case we can name no evidenced source of future earnings to value. This is a statement about what can be evidenced today, not a claim that OLC cannot succeed. The bear case adds the disclosed risk of another manufacturing rejection and further share issuance, which dilutes owners, but we do not go below zero: the company has funded its losses mainly by selling stock, and it reported that its cash covers operations for more than 12 months. The company sold shares in 2025 to raise about $46.5 million of financing cash. What would make this wrong. If OLC is approved and sells well, shares could be worth well above zero. The valuation would be revisited once the FDA has approved the drug, the manufacturing site has passed inspection, and reported cash flow from operations turns positive after stock compensation. The company did a 1-for-10 reverse stock split in June 2025, so per-share figures for earlier years are shown on that basis. Until that condition is met, no positive margin-of-safety price is supported.